Treatment options for relapsed Waldenstrom's Macroglobulinemia

被引：0
|
作者：
Grunenberg, Alexander [1 ]
Buske, Christian [1 ,2 ]
机构：
[1] Univ Hosp Ulm, Dept Internal Med 3, Ulm, Germany
[2] Univ Hosp Ulm, CCC Ulm, Inst Expt Canc Res, Ulm, Germany
来源：
HEMASPHERE | 2019年 / 3卷
关键词：
RITUXIMAB; IBRUTINIB;
D O I：
10.1097/HS9.0000000000000221
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Take home messages There are several treatment approaches available for relapsed WM patients. The choice of treatment for relapsed patients should be adapted to the fitness of patients, the previous therapy and the duration of response after last treatment. Rituximab based regimens, Bortezomib containing regimens, and Ibrutinib are well tolerated and efficient treatment options in relapsed WM patients. The future goal is the development of chemotherapy-free approaches which are active independent from the genotype and are applied for a limited duration of time.
引用
收藏
页码：65 / 67
页数：3
相关论文
共 50 条
  • [41] Evaluating ibrutinib in the treatment of symptomatic Waldenstrom's macroglobulinemia
    Papanota, Aristea-Maria
    Ntanasis-Stathopoulos, Ioannis
    Kastritis, Efstathios
    Dimopoulos, Meletios A.
    Gavriatopoulou, Maria
    [J]. JOURNAL OF BLOOD MEDICINE, 2019, 10 : 291 - 300
  • [42] Second treatment with fludarabine in a Waldenstrom's macroglobulinemia patient
    Maloisel, F
    Campos, F
    Giron, C
    Dufour, P
    [J]. LEUKEMIA, 2000, 14 (01) : 220 - 220
  • [43] Evaluating Patients' Preferences Regarding Treatment Options for Waldenstrom's Macroglobulinemia, a Discrete-Choice-Experiment
    Amaador, Karima
    Nieuwkerk, Pythia
    Minnema, Monique C.
    Kersten, Marie Jose
    Vos, Josephine M. I.
    [J]. BLOOD, 2021, 138
  • [44] Impact of Rituximab On the Treatment of Waldenstrom's Macroglobulinemia (WM)
    Thomas, Sheeba K.
    Delasalle, Kay B.
    Shah, Jatin J.
    Wang, Luhua
    Orlowski, Robert Z.
    Weber, Donna M.
    [J]. BLOOD, 2012, 120 (21)
  • [45] Allogeneic Transplantation for Relapsed Waldenstrom Macroglobulinemia and Lymphoplasmacytic Lymphoma
    Cornell, Robert F.
    Bachanova, Veronika
    D'Souza, Anita
    Woo-Ahn, Kwang
    Martens, Michael
    Huang, Jiaxing
    Al-Homsi, A. Samer
    Chhabra, Saurabh
    Copelan, Edward
    Diaz, Miguel-Angel
    Freytes, Cesar O.
    Gale, Robert Peter
    Ganguly, Siddhartha
    Hamadani, Mehdi
    Hildebrandt, Gerhard
    Kamble, Rammurti T.
    Kharfan-Dabaja, Mohamed
    Kindwall-Keller, Tamila
    Lazarus, Hillard M.
    Marks, David I.
    Nishihori, Taiga
    Olsson, Richard F.
    Saad, Ayman
    Usmani, Saad
    Vesole, David H.
    Yared, Jean
    Mark, Tomer
    Nieto, Yago
    Hari, Parameswaran
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2017, 23 (01) : 60 - 66
  • [46] Treatment of Waldenstrom's macroglobulinemia with stem cell transplantation
    Dreger, P
    Glass, B
    von Neuhoff, N
    Uharek, L
    Zeis, M
    Schmitz, N
    [J]. ANNALS OF ONCOLOGY, 1998, 9 : 109 - 109
  • [47] Are New Treatment Options Shifting How and When We Treat Waldenstrom Macroglobulinemia?
    Gertz, Morie A.
    [J]. AMERICAN JOURNAL OF HEMATOLOGY-ONCOLOGY, 2016, 12 (05) : 16 - 19
  • [48] Zanubrutinib for the treatment of Waldenstrom Macroglobulinemia
    Lim, Kenneth J. C.
    Tam, Constantine S.
    [J]. EXPERT REVIEW OF HEMATOLOGY, 2020, 13 (12) : 1303 - 1310
  • [49] Waldenstrom Macroglobulinemia: A Myriad of Effective Treatment Options, but Still Work to be Done Preface
    Castillo, Jorge J.
    Sarosiek, Shayna
    Kapoor, Prashant
    [J]. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2023, 37 (04) : XIII - XIV
  • [50] Treatment of Waldenstrom's macroglobulinemia with the combination of fludarabine and cyclophosphamide
    Dimopoulos, MA
    Hamilos, G
    Efstathiou, E
    Siapkaras, I
    Matsouka, C
    Gika, D
    Grigoraki, V
    Papadimitriou, C
    Mitsibounas, D
    Anagnostopoulos, N
    [J]. LEUKEMIA & LYMPHOMA, 2003, 44 (06) : 993 - 996
12345